secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001384101-26-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M
-----------------------------------------------------------------------------

- FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.
- Decipher volume +27% to ~102K; Afirma volume +11% to ~67.7K in FY2025.
- Prelim FY2025 adj EBITDA margin >25%; FY2026 margin guided at 25%.
- FY2026 total revenue guidance 10-13% growth ($570M-$582M); testing rev +14-16% ($559M-$569M excl. new tests).
- CEO cites upcoming US launch of Prosigna and TrueMRD as growth catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000002/0001384101-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000002/vcyt-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001384101-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer